U.K., Sept. 9 -- Covid-19 has exposed large vulnerabilities in the pharmaceutical supply chain within the US, this has prompted some organisations to relocate portions of their supply in an attempt to plan for the unexpected in the future.
With a huge spike in the requirements of PPE, test kits, and drugs, The Boyd Company has pinpointed a weakness in supply chains dependent on offshore suppliers. This weakness is also an opportunity for the 12 states that contain the 25 East-Coast cities Boyd has identified as well-positioned to benefit from this new wave of local pharma investment.
According to Janet Woodcock, Director - Center for Drug Evaluation and Research, only 28 percent of the manufacturing facilities making APIs to supply the U....